Pharmacokinetic and pharmacodynamic variations of acenocoumarol orally administrated either once or twice daily in patients with deep venous thrombosis.
The literature suggests that variations in anticoagulant effect occur when acenocoumarol is administrated in a daily dose. We assessed the anticoagulant effects of acenocoumarol with INR, factors VII and X and protein C in 12 randomly selected hospitalised patients with deep-vein thrombosis, six of them receiving a daily dose of acenocoumarol, the other six receiving twice daily doses. When the drug effect had been at a steady-state for at least 72 h, five blood samples were drawn per patient over a period of 24 h. No nycthemeral significant variations were noted for INR, factor X and protein C in the two groups (P > 0.10). Nycthemeral significant variation in factor VII when acenocoumarol was administered once daily was noted (P = 0.02), but the clinical relevance of factor VII variation at steady-state is uncertain. In spite of the short pharmacokinetic half-life of acenocoumarol, a stable nycthemeral pharmacodynamic activity was observed after once daily administration; twice-daily administration of acenocoumarol does not appear to be justified.
Mismetti
P
P
Unité de Pharmacologie Clinique, CHU Saint-Etienne Bellevue, France.
Reynaud
J
J
Laporte-Simitsidis
S
S
Thijssen
H
H
Tardy-Poncet
B
B
Tardy
B
B
Buchmuller
A
A
Decousus
H
H
D000074:Acenocoumarol / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D020246:Venous Thrombosis / Q000188:drug therapy / Q000378:metabolism*
D000925:Anticoagulants; D000074:Acenocoumarol